<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> after <z:hpo ids='HP_0002138'>subarachnoid haemorrhage</z:hpo> (SAH) responds poorly to systemic administration of <z:chebi fb="0" ids="50075">dihydropyridine</z:chebi> calcium <z:chebi fb="68" ids="48706">antagonists</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>However, the spastic arteries can be dilated by the topical (intrathecal) administration of the drugs </plain></SENT>
<SENT sid="2" pm="."><plain>We examined by angiography the spasmolytic effects of intrathecal (cisternal) administration of nicardipine (0.1 mg 1 ml ) or <z:chebi fb="1" ids="7565">nifedipine</z:chebi> (0.1 mg 1 ml ) on day 7 of SAH made by the two-haemorrhage model in dogs </plain></SENT>
<SENT sid="3" pm="."><plain>Both drugs dilated the spastic basilar artery from 15 min till 4 hours after the drug administration </plain></SENT>
<SENT sid="4" pm="."><plain>The increase in the diameter of the basilar artery between 1 and 3 hours was statistically significant in both groups </plain></SENT>
<SENT sid="5" pm="."><plain>Intrathecal administration of nicardipine which is water soluble, may be useful in the treatment of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> in patients </plain></SENT>
</text></document>